Brought to you by 
Stem Cell Therapeutics buys Trillium Therapeutics for $Cdn2.8mm
06 May 2016
Executive Summary
Stem Cell Therapeutics Corp. will acquire privately held Trillium Therapeutics Inc., which focuses on immune regulation and cytoprotection in its oncology drug development efforts. The merger could create Canada’s first public cancer stem cell company.
Deal Industry
- Pharmaceuticals
-
Biotechnology
-
Large Molecule
- Antibodies
-
Large Molecule
Deal Status
- Final
Deal Type
-
Acquisition
- Acquisition of Private Biotech
- Full Acquisition
- Intra-Biotech Deal
- Payment Includes Cash
- Payment Includes Stock
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Stem Cell Therapeutics buys Trillium Therapeutics for $Cdn2.8mm
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice